Clinical Trials

57 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02229084 2024-11-07

Vaccination of High Risk Breast Cancer Patients

58 enrolled 27 charts

Breast Neoplasms

NCT02938442 2024-11-07

Vaccination of Triple Negative Breast Cancer Patients

16 enrolled 30 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03013504 2024-11-06

TROIKA

503 enrolled

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT00719173 2024-11-04

NRR

Phase 1 Completed

19 enrolled

Breast Neoplasms, Nausea, Vomiting

NCT03164993 2024-10-15

ALICE

68 enrolled

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT03409198 2024-10-15

ICON

82 enrolled

Breast Neoplasms, Neoplasms

NCT04187898 2024-09-19

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Phase 1 Completed

59 enrolled

Breast Neoplasms, Neutropenia

NCT01606241 2024-08-21

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Completed

24 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

108 enrolled 7 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 1 FDA

Breast Neoplasms

NCT06373744 2024-04-18

Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

Completed

597 enrolled

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT00003782 2024-03-21

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

5,351 enrolled 8 charts

Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

24 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00036868 2024-03-08

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

90 enrolled

Breast Neoplasms

NCT03752723 2024-03-05

KEYNOTE-899

84 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02954055 2024-02-26

METEORA-II

140 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

126 enrolled 16 charts

Breast Neoplasms

NCT00630032 2024-02-21

TavIx

762 enrolled 14 charts

Breast Neoplasms

NCT02583828 2024-02-07

Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients

Phase NA Completed

200 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04350021 2024-01-17

METRO

Completed

40 enrolled

Breast Cancer Metastatic

NCT03742986 2023-12-19

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

8 enrolled 10 charts

Breast Neoplasms

NCT00525759 2023-11-24

ANZAC

40 enrolled

Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT00577122 2023-10-16

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

30 enrolled 13 charts

Breast Neoplasms

NCT00499083 2023-09-29

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

17 enrolled 5 charts